Risdiplam is the one orally administered drug authorised for the treatment method of SMA. It was FDA authorized in 2020 for use in people two months of age and older, and it features as an SMN2 gene splicing modifier resulting in higher levels of SMN protein. Oral administration is a https://charliep530fjo3.blazingblog.com/profile